| Stereochemistry | ABSOLUTE |
| Molecular Formula | C38H64O49S7 |
| Molecular Weight | 1529.34 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 25 / 25 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]5(O[C@H]1[C@H](OC)[C@@H](OC)[C@]([H])(O[C@@H]2[C@@H](COS(O)(=O)=O)O[C@]([H])(O[C@H]3[C@H](OC)[C@@H](OC)[C@]([H])(O[C@@H]4[C@@H](COS(O)(=O)=O)O[C@H](OC)[C@H](OS(O)(=O)=O)[C@H]4OS(O)(=O)=O)O[C@H]3C(O)=O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)O[C@@H]1C(O)=O)O[C@H](COS(O)(=O)=O)[C@@H](OC)[C@H](OC)[C@H]5OC
InChI
InChIKey=AJBMORBNKXNZSF-COSHMZDQSA-N
InChI=1S/C38H64O49S7/c1-64-15-12(9-72-88(43,44)45)76-35(27(68-5)18(15)65-2)80-21-19(66-3)28(69-6)37(82-25(21)32(39)40)79-17-14(11-74-90(49,50)51)77-38(31(87-94(61,62)63)24(17)85-92(55,56)57)81-22-20(67-4)29(70-7)36(83-26(22)33(41)42)78-16-13(10-73-89(46,47)48)75-34(71-8)30(86-93(58,59)60)23(16)84-91(52,53)54/h12-31,34-38H,9-11H2,1-8H3,(H,39,40)(H,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)/t12-,13-,14-,15-,16-,17-,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-,31-,34+,35-,36-,37-,38-/m1/s1
| Molecular Formula | C38H64O49S7 |
| Molecular Weight | 1529.34 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 25 / 25 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug.
Originator
Approval Year
PubMed
Sample Use Guides
The administration of idraparinux in subcutaneous fixed doses of 2.5 mg once weekly was found to be as effective and safe as conventional antithrombotic therapy in the initial treatment of patients with deep vein thrombosis, but less effective than standard therapy in the initial treatment of patients with primary pulmonary embolism
Route of Administration:
Other
